Abstract
DSM PHARMACEUTICAL PRODucts is restructuring its pharma chemicals and biologies units, discontinuing operations at its pharmaceutical chemicals plant in South Haven, Mich., in the first half of 2007, and mothballing its biologics facility in Montreal in the beginning of this year. The moves will result in the loss of 142 jobs in South Haven and 85 in Montreal. They are taking place as part of a DSM review process called Vision 2010 that, among other things, aims to better position the company's contract manufacturing business. In announcing the Michigan shutdown, DSM said it has determined that the markets for generic pharmaceutical chemicals and early-stage, nonregistered intermediates are commoditizing and will increasingly be served by Asian producers. The company, which acquired the Michigan plant as part of its 2000 acquisition of Catarytica, will consolidate production of pharmaceutical chemicals in Linz, Austria, and Venlo, the Netherlands. In biologics, DSM says it will emphasize ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
